Calvo A - Search Results

1

Truncated area under the urinary excretion rate curve in the evaluation of alendronate bioequivalence after a single dose in healthy volunteers.

Portolés A, Prieto E, Calvo A, Laredo L, Fernández N, Vargas E. Portolés A, et al. Among authors: calvo a. Arzneimittelforschung. 2009;59(8):397-402. doi: 10.1055/s-0031-1296414. Arzneimittelforschung. 2009. PMID: 19813462 Clinical Trial.

2

Single and Multiple Dose PK-PD Characterization for Carisoprodol. Part I: Pharmacokinetics, Metabolites, and 2C19 Phenotype Influence. Double-Blind, Placebo-Controlled Clinical Trial in Healthy Volunteers.

Calvo A, Alonso S, Prieto E, Ascaso-Del-Rio A, Ortuño J, Fernandez N, Portolés A. Calvo A, et al. J Clin Med. 2022 Feb 6;11(3):858. doi: 10.3390/jcm11030858. J Clin Med. 2022. PMID: 35160309 Free PMC article.

3

Carisoprodol Single and Multiple Dose PK-PD. Part II: Pharmacodynamics Evaluation Method for Central Muscle Relaxants. Double-Blind Placebo-Controlled Clinical Trial in Healthy Volunteers.

Calvo A, González-Hidalgo M, Terleira A, Fernández N, Portolés A. Calvo A, et al. J Clin Med. 2022 Feb 21;11(4):1141. doi: 10.3390/jcm11041141. J Clin Med. 2022. PMID: 35207414 Free PMC article.

4

Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial.

Portolés A, Terleira A, Calvo A, Martínez I, Resplandy G. Portolés A, et al. Among authors: calvo a. J Clin Pharmacol. 2006 Oct;46(10):1188-94. doi: 10.1177/0091270006291623. J Clin Pharmacol. 2006. PMID: 16988208 Clinical Trial.

5

Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial.

Portolés A, Calvo A, Terleira A, Laredo L, Resplandy G, Gorostiaga C, Moreno A. Portolés A, et al. Among authors: calvo a. J Clin Pharmacol. 2006 Oct;46(10):1195-203. doi: 10.1177/0091270006291624. J Clin Pharmacol. 2006. PMID: 16988209 Clinical Trial.

6

DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach.

Villalvazo P, Marzal-Alfaro B, García-Alfonso P, Revuelta-Herrero JL, Thomas F, López-Tarruella S, García-González X, Calvo A, Yakoubi M, Salvador-Martín S, López-López F, Aguilar I, Sanjurjo-Sáez M, Martín M, López-Fernández LA. Villalvazo P, et al. Among authors: calvo a. J Pers Med. 2021 Aug 13;11(8):792. doi: 10.3390/jpm11080792. J Pers Med. 2021. PMID: 34442436 Free PMC article.

7

First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers.

Felip E, Moreno V, Morgensztern D, Curigliano G, Rutkowski P, Trigo JM, Calvo A, Kowalski D, Cortinovis D, Plummer R, Maio M, Ascierto PA, Vladimirov VI, Cervantes A, Zudaire E, Hazra A, T'jollyn H, Bandyopadhyay N, Greger JG, Attiyeh E, Xie H, Calvo E. Felip E, et al. Among authors: calvo a, calvo e. Cancer Chemother Pharmacol. 2022 Apr;89(4):499-514. doi: 10.1007/s00280-022-04414-6. Epub 2022 Mar 17. Cancer Chemother Pharmacol. 2022. PMID: 35298698 Free PMC article. Clinical Trial.

8

Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry.

Valcarcel S, Gallego J, Jimenez-Fonseca P, Diez M, de Castro EM, Hernandez R, Arrazubi V, Custodio A, Cano JM, Montes AF, Macias I, Visa L, Calvo A, Tocino RV, Lago NM, Limón ML, Granja M, Gil M, Pimentel P, Macia-Rivas L, Pérez CH, Mangas M, Carnicero AM, Cerdà P, Gonzalez LG, Navalon FG, Rambla MDM, Richard MM, Carmona-Bayonas A. Valcarcel S, et al. Among authors: calvo a. J Cancer Res Clin Oncol. 2023 Jul;149(7):4077-4089. doi: 10.1007/s00432-022-04294-6. Epub 2022 Aug 30. J Cancer Res Clin Oncol. 2023. PMID: 36042046

9

Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors.

Márquez-Rodas I, Longo F, Rodriguez-Ruiz ME, Calles A, Ponce S, Jove M, Rubio-Viqueira B, Perez-Gracia JL, Gómez-Rueda A, López-Tarruella S, Ponz-Sarvise M, Álvarez R, Soria-Rivas A, de Miguel E, Ramos-Medina R, Castañon E, Gajate P, Sempere-Ortega C, Jiménez-Aguilar E, Aznar MA, Calvo A, Lopez-Casas PP, Martín-Algarra S, Martín M, Tersago D, Quintero M, Melero I. Márquez-Rodas I, et al. Among authors: calvo a. Sci Transl Med. 2020 Oct 14;12(565):eabb0391. doi: 10.1126/scitranslmed.abb0391. Sci Transl Med. 2020. PMID: 33055241

10

Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer.

Argilés G, André T, Hollebecque A, Calvo A, Dahan L, Cervantes A, Leger C, Amellal N, Fougeray R, Tabernero J. Argilés G, et al. Among authors: calvo a. Eur J Cancer. 2019 May;112:12-19. doi: 10.1016/j.ejca.2019.01.101. Epub 2019 Mar 16. Eur J Cancer. 2019. PMID: 30889492 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,139 results

Search Page

Filters